EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Immune-Related and Non-Immune-Related Acquired Factor XIII Deficiency

Akitada Ichinose iD

Seminars in Thrombosis and Hemostasis · 01.04.2026 · 52 (03) · 280-303

DOI: 10.1055/a-2633-0027 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Thrombosis and Hemostasis, erschienen am 01.04.2026. Verfasst von Akitada Ichinose. Beteiligte Einrichtung: Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan. Hauptthemen laut MEDLINE: Factor XIII Deficiency, Factor XIII. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 150 Literaturangaben. Gefördert von: the Japanese Ministry of Education, Culture, Sports, Science and Technology, the Japan Agency for Medical Research and Development, the Japanese Ministry of Health, Labor, and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coagulation factor XIII (FXIII) is an essential protein that stabilizes the hemostatic plug formed in the final stage of the coagulation reaction and controls its dissolution. In the blood, it exists as a heterotetramer consisting of A subunit dimers and B subunit dimers. Genetic defects in each subunit result in a congenital deficiency, which causes fatal or mild bleeding symptoms. Acquired FXIII deficiency can develop owing to reduced production or increased consumption of FXIII, and its severe form can cause various bleeding symptoms. In particular, autoimmune FXIII deficiency (AiF13D) causes fatal bleeding symptoms due to the suppression of FXIII activity by anti-FXIII autoantibodies and/or accelerated clearance of FXIII. AiF13D is characterized by extremely severe FXIII deficiency and severe bleeding symptoms. It is associated with the highest hemorrhagic mortality rate among autoimmune coagulation factor deficiencies, making it essential to differentiate it from other non-immune FXIII deficiencies (NiF13D), such as those arising from liver cirrhosis or leukemia. The probable and definitive diagnosis of AiF13D require the presence of FXIII inhibitors and anti-FXIII autoantibodies, respectively. FXIII inhibitors can be detected by a general FXIII activity assay in the mixed plasma of patients and healthy controls, and can be measured in a regular laboratory. In contrast, immunological assays are conducted in limited research facilities because they are not commercially available. NiF13D is usually treated by hemostatic therapy with FXIII concentrates, but AiF13D requires hemostatic therapy plus autoantibody eradication therapy with immunosuppressants. Since the disease often becomes resistant to treatment, long-term follow-up is strongly recommended.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor XIII DeficiencyFactor XIIIHumansAutoantibodies

Substanzen

Factor XIIIAutoantibodies

Autor:innen und Institutionen

  • Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan.
  • The Japanese Collaborative Research Group (JCRG) on Autoimmune Acquired Coagulation Factor Deficiencies supported by the Japanese Ministry of Health, Labor and Welfare (MHLW), Japan.

ORCID-Profile: Akitada Ichinose

Förderung

  • the Japanese Ministry of Education, Culture, Sports, Science and Technology
  • the Japan Agency for Medical Research and Development
  • the Japanese Ministry of Health, Labor, and Welfare

Zitieren

APA

Ichinose, A. (2026). Immune-Related and Non-Immune-Related Acquired Factor XIII Deficiency. Seminars in Thrombosis and Hemostasis, 52(03), 280-303. https://doi.org/10.1055/a-2633-0027

Vancouver

Ichinose A. Immune-Related and Non-Immune-Related Acquired Factor XIII Deficiency. Seminars in Thrombosis and Hemostasis. 2026;52(03):280-303. doi:10.1055/a-2633-0027

BibTeX
@article{Ichinose2026,
  author = {Ichinose, Akitada},
  title = {Immune-Related and Non-Immune-Related Acquired Factor XIII Deficiency},
  journal = {Seminars in Thrombosis and Hemostasis},
  year = {2026},
  volume = {52},
  number = {03},
  pages = {280--303},
  doi = {10.1055/a-2633-0027}
}
Kostenlos starten →